Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Silence Therapeutics Plc

Clinical trials sponsored by Silence Therapeutics Plc, explained in plain language.

Silence Therapeutics plc SLN NASDAQ

Biotech developing RNAi therapeutics for various diseases.

Trade on eToro (ad)

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Not yet finished but already full! 1

New RNA drug aims to reduce blood removal in polycythemia vera patients

Disease control Ongoing

This study tests a new drug called SLN124 in 69 adults with polycythemia vera, a condition where the body makes too many red blood cells. The drug works by blocking a protein that controls iron use, which may lower red blood cell production and reduce the need for regular blood r…

Phase: PHASE1, PHASE2 • Sponsor: Silence Therapeutics plc • Aim: Disease control

Last updated Jun 27, 2026 08:05 UTC